Valion Bio, Inc.
VBIO· Nasdaq
Who holds Valion Bio, Inc., from the managers’ Form 13F reports for the quarter ended Sep 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Marex Group Ltd | 94.4K | +73.9% | $264.3K | 0.1% | Nov 16, 2026 |
| Murchinson Ltd. | 31.8K | −72.3% | $89.1K | 0.1% | Nov 13, 2026 |
| UBS Group AG | 9K | −18.4% | $25.3K | 0% | Nov 10, 2026 |
| Tower Research Capital LLC (TRC) | 2.7K | +28.3% | $7.5K | 0.1% | Nov 16, 2026 |
| Robinhood Markets, Inc. | 707 | — | $2K | 0.1% | Nov 18, 2026 |
| SBI Securities Co., Ltd. | 53 | +231.3% | $148 | 0% | Oct 22, 2026 |
| Caitong International Asset Management Co., Ltd | 1 | ±0% | $3 | 0% | Oct 29, 2026 |
| Danske Bank A/S | 1 | New | $3 | 0% | Nov 9, 2026 |